文献速递前列腺癌

卡匹伐替尼联合多西他赛治疗转移性去势抵抗性前列腺癌的2期ProCAID临床试验总生存更新

Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial.
PubMed 文献 · Eur Urol · 2022-06-07

ProCAID是一项2期试验,评估在转移性去势抵抗性前列腺癌(mCRPC)患者的多西他赛治疗中加入AKT1/2/3抑制剂卡匹伐替尼。在意向治疗人群(n=150)发生66%事件后更新总生存(OS)数据:卡匹伐替尼联合多西他赛中位OS为25.3个月,安慰剂联合多西他赛为20.3个月(HR 0.70,95%CI 0.47-1.05;名义p=0.09)。

要点

  • 在意向治疗人群(n=150)中,卡匹伐替尼联合多西他赛较安慰剂联合多西他赛中位OS为25.3 vs 20.3个月(HR 0.70,95%CI 0.47-1.05;名义p=0.09)。
  • 在既往接受过阿比特龙和/或恩扎卢胺治疗的患者亚组中,卡匹伐替尼联合多西他赛较安慰剂联合多西他赛中位OS为25.0 vs 17.6个月(HR 0.57,95%CI 0.36-0.91;名义p=0.02)。
  • 在未接受过阿比特龙/恩扎卢胺治疗的患者中,卡匹伐替尼联合多西他赛较安慰剂联合多西他赛中位OS为31.1个月 vs 未达到(HR 1.43,95%CI 0.63-3.23)。

核心结论

  • 作者认为,在多西他赛基础上加用卡匹伐替尼可能延长总生存。
  • 探索性分析显示,在既往暴露于雄激素受体靶向药物的患者亚组中,总生存获益得以维持,该结果应在前瞻性试验中评估。

研究设计与样本

  • ProCAID是一项2期试验,评估在转移性去势抵抗性前列腺癌(mCRPC)患者的多西他赛治疗中加入AKT1/2/3抑制剂卡匹伐替尼。
  • 本次报告在意向治疗人群(n=150)中发生66%事件后的总生存数据。

主要发现

  • 卡匹伐替尼联合多西他赛较安慰剂联合多西他赛中位总生存为25.3个月 vs 20.3个月(HR 0.70,95%CI 0.47-1.05;名义p=0.09)。
  • 两治疗组接受后续延长生命治疗的情况均衡。
  • 在既往接受过阿比特龙和/或恩扎卢胺治疗的患者亚组中,卡匹伐替尼联合多西他赛较安慰剂联合多西他赛中位总生存为25.0个月 vs 17.6个月(HR 0.57,95%CI 0.36-0.91;名义p=0.02)。
  • 在未接受过阿比特龙/恩扎卢胺治疗的患者中,卡匹伐替尼联合多西他赛较安慰剂联合多西他赛中位总生存为31.1个月 vs 未达到(HR 1.43,95%CI 0.63-3.23)。
  • 此前已报告,卡匹伐替尼未延长复合无进展生存主要终点,但显著改善了总生存次要终点。

局限性

  • 探索性分析显示总生存获益在既往暴露于雄激素受体靶向药物的患者亚组中得以维持,作者认为该结果应在前瞻性试验中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The PI3K/AKT/PTEN pathway is frequently deregulated in metastatic castration-resistant prostate cancer (mCRPC). ProCAID was a phase 2 trial assessing addition of the AKT1/2/3 inhibitor capivasertib to docetaxel for patients with mCRPC. We previously reported that capivasertib did not extend a composite progression-free survival primary endpoint but did significantly improve the secondary endpoint of overall survival (OS). Here we present OS data after 66% of events had occurred in the intent-to-treat population (n = 150). Median OS was 25.3 mo for capivasertib plus docetaxel versus 20.3 mo for placebo plus docetaxel (hazard ratio [HR] 0.70, 95% confidence interval [CI] 0.47-1.05; nominal p = 0.09). Receipt of subsequent life-extending treatments was balanced between the treatment arms. The OS benefit associated with capivasertib was maintained in a subset of patients previously treated with abiraterone and/or enzalutamide (median OS 25.0 vs 17.6 mo; HR 0.57, 95% CI 0.36-0.91; nominal p = 0.02) but not in abiraterone/enzalutamide-naïve patients (median OS 31.1 mo vs not reached; HR 1.43, 95% CI 0.63-3.23). We conclude that OS may be extended by addition of capivasertib to docetaxel. Exploratory analysis revealed that the OS benefit was maintained in a subset of patients previously exposed to androgen receptor-targeted agents, which should be evaluated in prospective trials. PATIENT SUMMARY: The ProCAID study examined whether adding the AKT inhibitor drug capivasertib to docetaxel chemotherapy improves outcomes for patients with advanced prostate cancer. Initial analysis of the ProCAID results suggested that capivasertib improved overall survival benefit. This follow-up analysis suggests that capivasertib addition may be particularly beneficial for patients whose cancer was previously treated with drugs that target the androgen receptor.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Crabb SJ, Griffiths G, Dunkley D, et al. Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial. Eur Urol. 2022. PMID: 35688662. doi:10.1016/j.eururo.2022.05.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。